UBS Group’s Biohaven BHVN Stock Holding History

UBS Group’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-18,000	Closed	-$433K	–	10261
2025 Q1	$433K	Buy	+18,000	New	+$635K	﹤0.01%	5959

Other funds holding BHVN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's BHVN Position: Q2 2026 in Review

UBS Group increased its Biohaven (BHVN) stake by 77% in Q2 2026, buying an estimated $11.8M and bringing the position to 2,518,827 shares worth $37.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2038.

UBS Group first reported a position in BHVN in Q4 2022 and has held it in 15 quarters since. 296 funds tracked by Wall St. Rank hold BHVN as of Q2 2026.

UBS Group held 2,518,827 shares of Biohaven worth $37.5M as of Q2 2026.
UBS Group bought 1,092,400 Biohaven shares in Q2 2026, an estimated $11.8M.
Biohaven made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2038 holding.
UBS Group first reported a position in Biohaven in Q4 2022 and has held it in 15 quarters since.
296 funds tracked by Wall St. Rank held Biohaven as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.